These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10220615)

  • 41. Different benefits, different risks, equal cost.
    Colombo A
    Eur Heart J; 1999 Nov; 20(21):1531-2. PubMed ID: 10529320
    [No Abstract]   [Full Text] [Related]  

  • 42. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications.
    Mayer DM; Docktor WJ
    Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118
    [No Abstract]   [Full Text] [Related]  

  • 43. Abciximab: cost-effective survival advantage in clinical trials and clinical practice.
    Young JJ; Kereiakes DJ
    Am Heart J; 2000 Dec; 140(6 Suppl):S148-53. PubMed ID: 11100009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
    Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
    Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Khan SS; Forrester J
    N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
    [No Abstract]   [Full Text] [Related]  

  • 46. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelets and vascular thrombosis.
    Harker LA
    N Engl J Med; 1994 Apr; 330(14):1006-7. PubMed ID: 8121441
    [No Abstract]   [Full Text] [Related]  

  • 48. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The CAPTURE trial.
    Umans VA; Kloeg PH; Bronzwaer J
    Lancet; 1997 Aug; 350(9075):445. PubMed ID: 9259679
    [No Abstract]   [Full Text] [Related]  

  • 50. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
    Long KH; Ting HH; McMurtry EK; Lennon RJ; Wood DL; Holmes DR; Raveendran G; Rihal CS
    Value Health; 2008; 11(3):462-9. PubMed ID: 18489669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 52. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
    Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study.
    Prati F; Kwiatkowski P; Caroselli C; Imola F; Manzoli A; Fouad T; Corvo P; Ramazzotti V
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):165-9. PubMed ID: 16142802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
    Schwartz RS
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):170-2. PubMed ID: 16142803
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients.
    Lage MJ; Barber BL; McCollam PL; Bala M; Scherer J
    Catheter Cardiovasc Interv; 2001 Jul; 53(3):296-303. PubMed ID: 11458403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
    Lincoff AM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.